These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 7016300

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
    Pinsky CM, Camacho FJ, Kerr D, Geller NL, Klein FA, Herr HA, Whitmore WF, Oettgen HF.
    Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M, Olaru V.
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne FM.
    Urol Int; 1993 Dec; 51(2):67-72. PubMed ID: 8351757
    [Abstract] [Full Text] [Related]

  • 15. [Role of BCG in T1G3 bladder transitional cell carcinoma (TCC): our experience].
    Comeri GC, Belvisi P, Conti G, Cretarola E, Duvia R, Furgoni R, Gianneo E, Radice GP.
    Arch Ital Urol Androl; 1996 Feb; 68(1):55-9. PubMed ID: 8664924
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
    Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Simon J, Schulman CC.
    Eur Urol; 2000 Apr; 37(4):470-7. PubMed ID: 10765079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Intravesical bacillus Calmette-Guerin in the treatment of recurrent superficial bladder tumors].
    Nakano M, Iwamuro S, Fujii H, Kondoh I.
    Hinyokika Kiyo; 1988 Jun; 34(6):983-6. PubMed ID: 3223463
    [Abstract] [Full Text] [Related]

  • 20. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.